Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Persistence of symptoms up to 10 months following acute COVID-19 illness

View ORCID ProfileRoy H. Perlis, Jon Green, Mauricio Santillana, David Lazer, Katherine Ognyanova, Matthew Simonson, Matthew A. Baum, Alexi Quintana, Hanyu Chwe, James Druckman, John Della Volpe, Jennifer Lin
doi: https://doi.org/10.1101/2021.03.07.21253072
Roy H. Perlis
1Massachusetts General Hospital, Boston, MA
2Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roy H. Perlis
  • For correspondence: rperlis@mgh.harvard.edu
Jon Green
3Northeastern University, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauricio Santillana
4Harvard University, Cambridge, MA
5Boston Children’s Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Lazer
3Northeastern University, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine Ognyanova
6Rutgers University, New Brunswick, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Simonson
3Northeastern University, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew A. Baum
4Harvard University, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexi Quintana
3Northeastern University, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanyu Chwe
3Northeastern University, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Druckman
7Northwestern University, Evanston, IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Della Volpe
4Harvard University, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Lin
7Northwestern University, Evanston, IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance COVID-19 symptoms are increasingly recognized to persist among a subset of individual following acute infection, but features associated with this persistence are not well-understood.

Objective We aimed to identify individual features that predicted persistence of symptoms over at least 2 months at the time of survey completion.

Design: Non-probability internet survey. Participants were asked to identify features of acute illness as well as persistence of symptoms at time of study completion. We used logistic regression models to examine association between sociodemographic and clinical features and persistence of symptoms at or beyond 2 months.

Setting Ten waves of a fifty-state survey between June 13, 2020 and January 13, 2021.

Participants 6,211 individuals who reported symptomatic COVID-19 illness confirmed by positive test or clinician diagnosis.

Exposure symptomatic COVID-19 illness

Results Among 6,211 survey respondents reporting COVID-19 illness, with a mean age of 37.8 (SD 12.2) years and 45.1% female, 73.9% white, 10.0% Black, 9.9% Hispanic, and 3.1% Asian, a total of 4946 (79.6%) had recovered within less than 2 months, while 491 (7.9%) experienced symptoms for 2 months or more. Of the full cohort, 3.4% were symptomatic for 4 months or more and 2.2% for 6 months or more. In univariate analyses, individuals with persistent symptoms on average reported greater initial severity. In logistic regression models, older age was associated with greater risk of persistence (OR 1.10, 95% CI 1.01-1.19 for each decade beyond 40); otherwise, no significant associations with persistence were identified for gender, race/ethnicity, or income. Presence of headache was significantly associated with greater likelihood of persistence (OR 1.44, 95% CI 1.11-1.86), while fever was associated with diminished likelihood of persistence (OR 0.66, 95% CI 0.53-0.83).

Conclusion and Relevance A subset of individuals experience persistent symptoms from 2 to more than 10 months after acute COVID-19 illness, particularly those who recall headache and absence of fever. In light of this prevalence, strategies for predicting and managing such sequelae are needed.

Trial Registration NA

Question Which individuals are at greatest risk for post-acute sequelae of COVID-19?

Findings In this non-probability internet survey, among 6,211 individuals with symptomatic COVID-19 illness, 7.9% experienced persistence of symptoms lasting 2 months or longer. Older age, but not other sociodemographic features, was associated with risk for persistence, as was headache.

Meaning Identifying individuals at greater risk for symptomatic persistence may facilitate development of targeted interventions.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NA

Funding Statement

This study was supported by the National Institute of Mental Health (R01MH116270 and 1R56MH115187; Dr. Perlis) and the National Science Foundation (Dr. Ognyanova). The sponsors did not contribute to any aspect of study design, data collection, data analysis, or data interpretation. The authors had the final responsibility for the decision to submit for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was determined to be exempt by the Institutional Review Board of Harvard University; all participants signed consent online prior to survey access.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data are available upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 08, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Persistence of symptoms up to 10 months following acute COVID-19 illness
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Persistence of symptoms up to 10 months following acute COVID-19 illness
Roy H. Perlis, Jon Green, Mauricio Santillana, David Lazer, Katherine Ognyanova, Matthew Simonson, Matthew A. Baum, Alexi Quintana, Hanyu Chwe, James Druckman, John Della Volpe, Jennifer Lin
medRxiv 2021.03.07.21253072; doi: https://doi.org/10.1101/2021.03.07.21253072
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Persistence of symptoms up to 10 months following acute COVID-19 illness
Roy H. Perlis, Jon Green, Mauricio Santillana, David Lazer, Katherine Ognyanova, Matthew Simonson, Matthew A. Baum, Alexi Quintana, Hanyu Chwe, James Druckman, John Della Volpe, Jennifer Lin
medRxiv 2021.03.07.21253072; doi: https://doi.org/10.1101/2021.03.07.21253072

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (241)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1425)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (585)
  • Epidemiology (10307)
  • Forensic Medicine (6)
  • Gastroenterology (528)
  • Genetic and Genomic Medicine (2637)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1740)
  • Health Policy (790)
  • Health Systems and Quality Improvement (676)
  • Hematology (268)
  • HIV/AIDS (568)
  • Infectious Diseases (except HIV/AIDS) (12103)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2466)
  • Nursing (145)
  • Nutrition (379)
  • Obstetrics and Gynecology (493)
  • Occupational and Environmental Health (568)
  • Oncology (1327)
  • Ophthalmology (403)
  • Orthopedics (147)
  • Otolaryngology (238)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (784)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2405)
  • Public and Global Health (5018)
  • Radiology and Imaging (895)
  • Rehabilitation Medicine and Physical Therapy (530)
  • Respiratory Medicine (682)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (246)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)